Crinetics Pharmaceuticals, Inc.CRNXNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
42.50%
↓ 27% below average
Average (8y)
58.58%
Historical baseline
Range
High:165.13%
Low:0.00%
Volatility
281.9%
High variability
| Period | Value |
|---|---|
| 2024 | 42.50% |
| 2023 | 29.41% |
| 2022 | 54.56% |
| 2021 | 46.28% |
| 2020 | 38.77% |
| 2019 | 69.56% |
| 2018 | 165.13% |
| 2017 | 81.04% |
| 2016 | 0.00% |